Behavioural difficulties, end of treatment · obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global improvement · Individuals with autism spectrum disorder
Music therapy probably leads to higher global improvement compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Social interaction · Individuals with autism spectrum disorder
1 finding from 1 review
Non‐verbal communication · Individuals with autism spectrum disorder
1 finding from 1 review
Verbal communication · Individuals with autism spectrum disorder
1 finding from 1 review
Quality of life · Individuals with autism spectrum disorder
1 finding from 1 review
Autism symptom severity Measured by: parent‐reported autism symptoms on standardised autism screening and diagnostic instruments (lower scores indicate less severe autism symptoms) · Individuals with autism spectrum disorder
1 finding from 1 review
Adverse events Any serious or non‐serious adverse event · Individuals with autism spectrum disorder
Music therapy showed no clear difference in adverse events Any serious or non‐serious adverse event compared with placebo therapy or standard care (moderate certainty).
1 finding from 1 review
Intervention not reported
Aggression OAS, OAS‐M, MOAS, self‐reported incidents, CPRS subscale (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Impulsivity Q‐sort, Porteus Maze Test (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Hostility BPRS hostility sub scale, CPRS hostility subscale, Q‐sort, speech content analysis (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Anger Self‐reported outbursts, Rosenweig Picture Frustration Test (endpoints fall between 2 weeks and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Anger‐Hostility POMS anger‐hostility subscale (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Non‐compliance leaving the study early (endpoints fall between 1 and 6 months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Intervention not reported
Adverse events, any (endpoints fall between 1 6 six months) · Any individual experiencing recurrent aggressive outbursts or episodes
1 finding from 1 review
Impaired social interaction · children aged 5 to 11 years with ASD
1 finding from 1 review
Social communication impairment · children aged 5 to 11 years with ASD
1 finding from 1 review
Stereotyped patterns of behaviour and interests · children aged 5 to 11 years with ASD
1 finding from 1 review
Total adverse events · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Non‐core symptoms of ASD · children aged 5 to 11 years with ASD
D‐cycloserine showed no clear difference in non‐core symptoms of ASD compared with placebo (low certainty).
1 finding from 1 review